NCT00381940View on ClinicalTrials.gov

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

December 31, 2016

Conditions
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nodular Lymphocyte Predominant Hodgkin LymphomaAdult Nodular Sclerosis Hodgkin LymphomaChildhood Lymphocyte Depletion Hodgkin LymphomaChildhood Lymphocyte Predominant Hodgkin LymphomaChildhood Mixed Cellularity Hodgkin LymphomaChildhood Nodular Lymphocyte Predominant Hodgkin LymphomaChildhood Nodular Sclerosis Hodgkin LymphomaRecurrent Adult Hodgkin LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaStage I Adult Hodgkin LymphomaStage I Childhood Hodgkin LymphomaStage II Adult Hodgkin LymphomaStage II Childhood Hodgkin LymphomaStage III Adult Hodgkin LymphomaStage III Childhood Hodgkin LymphomaStage IV Adult Hodgkin LymphomaStage IV Childhood Hodgkin Lymphoma
Interventions
DRUG

ifosfamide

Given IV

DRUG

bortezomib

Given IV

DRUG

vinorelbine tartrate

Given IV

BIOLOGICAL

filgrastim

Given IV or SC

Trial Locations (1)

19104

Children's Oncology Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00381940 - Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy | Biotech Hunter | Biotech Hunter